Send to Friend

FromTo


Send to Friend from I-Congress

Inflammatory Bowel Diseases 2009

ECCO-Logo

Inflammatory Bowel Diseases 2009

4th Congress of ECCO -
the European Crohn's and Colitis Organisation

February 5th-7th, 2009
CCH Congress Center Hamburg, Germany

Impressions - Final Program

 

Presentations

For the author`s scientific profile at BIOMEDEXPERTS, please click author

 

Colonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatment

Ingrid Arijs1,2, L. Van Lommel2, K. Van Steen4, G. De Hertogh3, R. Quintens2 , G. Van Assche
1, S. Vermeire1, K. Geboes3, Schuit2 and P. Rutgeerts1

1Gastroenterology, 3Morphology and Molecular Pathology, University Hospital Gasthuisberg, Leuven, Belgium; 2Gene Expression Unit, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Leuven, Belgium; 4Department of Electrical Engineering and Computer Science (Montefiore Institute), University of Liege, Liege, Belgium.

Start Presentation »

 

T-cell selective inhibition of gut pro-inflammatory cytokine production by a Ca2+ release-activated Ca2+ channel blocker in inflammatory bowel

Antonio Di Sabatino, Laurens Kruidenier, Laura Rovedatti, Nickolas Leakey, Michael Wilson, Lisa Lione, Charles Knowles, Kevin Lee, Peter McLean, Gino R. Corazza, Thomas T. MacDonald

Clinica Medica I, Fondazione IRCCS Policlinico S. Matteo;Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche Intestinali, University of Pavia; Centre for Infectious Disease, ICMS, Barts and the London School of Medicine and Dentistry, London, UK; Immuno-Inflammation CEDD, GlaxoSmithKline, UK.

Start Presentation »

 

The unmet therapeutic need in IBD: the Japanese perspective

Toshifumi Hibi

Division of Gastroenterology and Hepatology, Department of Internal Medicine Keio University School of Medicine, Tokyo, Japan

Start Presentation »

 

How do anti-inflammatory therapies work? - Back from the bedside to the bench

Britta Siegmund

Charité Campus Benjamin Franklin, Berlin, Germany

Start Presentation »

 

The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6

Vetrano Stefania, Borroni EM, Bonecchi R1, Correale C, Sarukhan A, Arena V, Fantini M, Roncalli M, Repici A, Mantovani A, Locati M and Danese S

IBD Research Unit, Istituto Clinico Humanitas, Rozzano, Milan; Italy

Start Presentation »

 

Changing gut flora: Aetiologic & therapeutic implications

Patricia Lepage1 and Herbert Tilg2

1Biodiversity and Metagenomics, Ecology and Physiology of the GIT INRA – Jouy-en-Josas Research Center
2Department of Medicine, Christian Doppler Research Laboratory for Gut Inflammation, Hall in Tirol/Innsbruck, Austria

Start Presentation »

 

Temporal stability of faecal microbiota with IS-pro; a novel method

Matthijs E. Grasman1, A.E. Budding2, C.J.J. Mulder1, C.M.J.E. Vandenbroucke-Grauls2, P.H.M. Savelkoul2, A.A. van Bodegraven1

1Dept. of Gastroenterology and Hepatology, 2Dept. of Medical Microbiology and Infection Control, VU University Medical Centre, Amsterdam, The Netherlands

Start Presentation »

 

Role of small bowel endoscopy in the management of patients with IBD:
international ECCO-OMED consensus

Ana Ignjatovic, Arnaud Bourreille, Simon Travis, Jean-Frederic Colombel, Andre Van Gossum

on behalf of the Organisation Mondial d’Endoscopie Digestive (OMED) and the European Crohn’s and Colitis Organisation (ECCO)

Start Presentation »

 

Immunomodulators in IBD: Is there a price to pay?

Gert Van Assche

Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium

Start Presentation »

 

Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis:
the CESAME prospective data

Laurent Beaugerie, Ph Seksik and F. Carrat

for the CESAME Study Group, Saint-Antoine hospital, Paris, France

Start Presentation »

 

Stress in IBD:The overlooked villain

David Rampton

Barts and the London Queen Mary`s School of Medicine and Dentistry, London, United Kingdom

Start Presentation »

 

Role of TAK1 in Crohn’s disease: a new molecular marker of fibrosis?

Alessia R. Grillo

Padua, Italy

Start Presentation »

 

The right use of diagnostics: How not to harm the patient?

Edouard Louis

Gastroenterology Department, CHU Liège, GIGAresearch, University of Liège

Start Presentation »

 

Crohn`s disease : Where it all started and where it`s all going

Lloyd Mayer

New York, United States of America

Start Presentation »

 

Clinical Course and Cost of Care in Ulcerative Colitis
Markov Chain Analysis of a European Prospective Population-Based Cohort

Selwyn Odes1, H. Vardi2, M. Friger2, P. Munkholm3, D. Esser4, M. Elkjaer3, H. Waters5, E. Langholz6

1Gastroenterology, Soroka Medical Center, Ben Gurion University, Beer Sheva, Israel; 2Epidemiology, Ben Gurion University, Beer Sheva, Israel; 3Gastroenterology, Herlev University Hospital, Copenhagen, Denmark; 4Centocor BV, Leiden, Netherlands; 5Centocor Ortho Biotech Services, Malvern, PA, USA; 6Gastroenterology, Gentofte Hospital, Copenhagen, Denmark

Start Presentation »

 

Fistulizing Crohn’s Disease

Dario Sorrentino

Chair of Gastroenterology, University of Udine Medical School, Udine, Italy

Start Presentation »

 

ECCO Crohn’s Disease Consensus 2008:
paediatric / adolescent disease, pregnancy and psychosomatics

James Lindsay

Digestive Diseases Clinical Academic Unit, Barts and the London NHS Trust London, UK

Start Presentation »